Edwards Lifesciences

EWleader

Edwards Lifesciences is the global leader in transcatheter heart valve therapies, particularly TAVR, which has transformed treatment for aortic stenosis from open-heart surgery to a catheter-based procedure.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($6.4B)

静态数据（加载实时财务…）

Transcatheter Aortic Valve (60%)

Surgical Structural Heart (15%)

Critical Care (15%)

TMTT (10%)

业务板块构成与主要客户

产品详情

TAVR (SAPIEN)60%

Transcatheter aortic valve replacement systems for heart valve disease

TMTT10%

Transcatheter mitral and tricuspid valve therapies in development

Surgical Structural Heart15%

Surgical heart valves and repair products

Critical Care15%

Hemodynamic monitoring and smart recovery technologies

供应链关系

竞争对手

Medtronic

CoreValve TAVR system

影响: Primary TAVR competitor

Abbott Laboratories

Structural heart portfolio

影响: Growing competitor in structural heart

Boston Scientific

ACURATE valve

影响: Emerging TAVR competitor

宏观与市场背景

헬스케어行业新闻

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

近期催化剂

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

AI 分析

点击「获取 AI 分析」以获得 Edwards Lifesciences 的 AI 供应链分析。

企业信息

总部

Irvine, California, USA

成立时间

1958

员工人数

20,000+

官网

edwards.com

行业概况 — 헬스케어

行业新闻